| Schedule of Presents Major Accounts of Statements of Operations |
The following table presents major accounts of
statements of operations by segments for the year ended December 31, 2024.
| | |
MDMOOC
Services | | |
Sales of
patented
drugs | | |
Total | |
| Revenues | |
$ | 13,712,964 | | |
$ | 2,151,809 | | |
$ | 15,864,773 | |
| Cost of revenues | |
| (5,510,088 | ) | |
| (1,442,472 | ) | |
| (6,952,560 | ) |
| Selling and marketing expenses | |
| (3,799,558 | ) | |
| (210,824 | ) | |
| (4,010,382 | ) |
| General and administrative expenses | |
| (4,815,112 | ) | |
| (174,672 | ) | |
| (4,989,784 | ) |
| Research and development expenses | |
| (252,451 | ) | |
| - | | |
| (252,451 | ) |
| Loss from disposal of property and equipment | |
| (863 | ) | |
| - | | |
| (863 | ) |
| Total operating expenses | |
$ | (8,867,984 | ) | |
$ | (385,496 | ) | |
$ | (9,253,480 | ) |
| Segment operating (loss) income | |
$ | (665,108 | ) | |
$ | 323,841 | | |
$ | (341,267 | ) |
| | |
| | | |
| | | |
| | |
| Interest income, net | |
| 242,848 | | |
| 160 | | |
| 243,008 | |
| Other income, net | |
| 148,089 | | |
| 11,926 | | |
| 160,015 | |
| Segment net (loss) income | |
$ | (622,577 | ) | |
$ | 349,164 | | |
$ | (273,413 | ) |
The following table presents major accounts of
statements of operations by segments for the year ended December 31, 2023.
| | |
MDMOOC Services | | |
Sales of patented drugs | | |
Total | |
| Revenues | |
$ | 10,406,734 | | |
$ | 9,027,211 | | |
$ | 19,433,945 | |
| Cost of revenues | |
| (5,162,438 | ) | |
| (5,759,315 | ) | |
| (10,921,753 | ) |
| Selling and marketing expenses | |
| (5,327,266 | ) | |
| (1,383,491 | ) | |
| (6,710,757 | ) |
| General and administrative expenses | |
| (6,470,944 | ) | |
| (226,365 | ) | |
| (6,697,309 | ) |
| Research and development expenses | |
| (514,411 | ) | |
| - | | |
| (514,411 | ) |
| Loss from disposal of property and equipment | |
| (1,719,442 | ) | |
| - | | |
| (1,719,442 | ) |
| Impairment of goodwill | |
| (5,617,865 | ) | |
| - | | |
| (5,617,865 | ) |
| Impairment of intangible assets | |
| (536,206 | ) | |
| - | | |
| (536,206 | ) |
| Total operating expenses | |
$ | (20,186,134 | ) | |
$ | (1,609,856 | ) | |
$ | (21,795,990 | ) |
| Segment operating (loss) income | |
$ | (14,941,838 | ) | |
$ | 1,658,040 | | |
$ | (13,283,798 | ) |
| | |
| | | |
| | | |
| | |
| Interest income, net | |
| 216,528 | | |
| 20,526 | | |
| 237,054 | |
| Other income, net | |
| 1,069,603 | | |
| 142 | | |
| 1,069,745 | |
| Segment net (loss) income | |
$ | (12,955,659 | ) | |
$ | 1,648,420 | | |
$ | (11,307,239 | ) |
The following table presents major accounts of
statements of operations by segments for the year ended December 31, 2022.
| | |
MDMOOC
Services | | |
Sales of
patented
drugs | | |
Total | |
| Revenues | |
$ | 12,935,420 | | |
$ | 1,216,096 | | |
$ | 14,151,516 | |
| Cost of revenues | |
| (7,166,871 | ) | |
| (627,981 | ) | |
| (7,794,852 | ) |
| Selling and marketing expenses | |
| (2,091,943 | ) | |
| (8,025 | ) | |
| (2,099,968 | ) |
| General and administrative expenses | |
| (6,649,906 | ) | |
| (149,728 | ) | |
| (6,799,634 | ) |
| Research and development expenses | |
| (411,524 | ) | |
| - | | |
| (411,524 | ) |
| Total operating expenses | |
$ | (9,153,373 | ) | |
$ | (157,753 | ) | |
$ | (9,311,126 | ) |
| Segment operating (loss) income | |
$ | (3,384,824 | ) | |
$ | 430,362 | | |
$ | (2,954,462 | ) |
| | |
| | | |
| | | |
| | |
| Interest income, net | |
| 141,866 | | |
| 148 | | |
| 142,014 | |
| Other income, net | |
| 262,131 | | |
| 311 | | |
| 262,442 | |
| Segment net (loss) income | |
$ | (3,235,426 | ) | |
$ | 413,107 | | |
$ | (2,822,319 | ) |
|